Search results for: Innovation Policy Prize

Events

Our varied portfolio of global events share research and innovations from the frontiers of the health and life sciences sector. From webinars to our lectures our network of world-leading experts…

‘HispaNICE’: the Creation of an ‘Independent Authority for the Evaluation of Health Practices and Policies’ Gathers Momentum

24 February 2021

…Minister of Health of the Basque Country, and member of OHE Policy Committee); Félix Lobo (President of the Spanish National Health System’s Advisory Committee on Pharmaceutical Provision Financing); former presidents…

Time to Tackle the Challenges around Combination Therapies for Cancer

29 March 2021

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of shorter regimens will take…

ISPOR Issue Panel Roundup: Are Our HTA Methods Fit for Purpose for Gene Therapies?

6 June 2022

…the current HTA landscape provides an appropriate reward and therefore incentive for innovation, and how that reward should optimally be determined. He concluded that our current methods offer a good…

Health and the Use of Medicines in Primary Care in Wales

1 November 2011

In this, report commissioned by the ABPI in Wales, OHE Consulting examines the use of medicines in primary care in Wales since 2000 compared to the other countries of the…

Around the World in HTAs: Canada – Autonomous yet Collaborative

9 April 2025

…provinces and territories. From CCOHTA in the 1990s to today’s CDA-AMC, HTA processes in Canada have evolved to include greater patient involvement in decision-making and to adopt innovations from other…

Is There a Productivity Crisis in Pharmaceutical R&D?

6 January 2012

This Seminar Briefing recounts the key points made by Prof Riccaboni, from the University of Trento, at a recent OHE Lunchtime Seminar. It focuses primarily on the reasons for a…

Medicines in the 1990s: a Technological Forecast

1 July 1969

By 1990, the total cost of the National Health Service will probably have reached about £10,000 million of which about £1,300 million will be for medicines prescribed by general practitioners…

Henry Fong

2 October 2024

…His master’s dissertation focused on the economic evaluation of a digital health application for periodontitis in Germany. Henry is interested in understanding the value of pharmaceutical innovations and decision-making in…